TRANYLCYPROMINE, a monoamine oxidase inhibitor, was introduced in 1961 for the treatment of certain depressive disorders. In its initial evaluation,1,2 the Council stated that "the agent has not been used for a sufficiently long time to assess the possible toxic effects that may result from its prolonged administration." Following several reports of alarming adverse reactions associated with the use of this drug, the Council called attention to the fact that paradoxical hypertension may occur.3 Because of additional reports of hypertensive crises with intracranial bleeding resulting in the death of a number of patients, tranylcypromine was withdrawn from the market in February, 1964. The drug has now been reintroduced with more limited indications for its use and with greater stress on the precautions to be observed. The following statement, which takes these recent reports into account, represents the Council's revised monograph on tranylcypromine.
Actions and Uses
The use of
Reevaluation of Tranylcypromine Sulfate(Parnate Sulfate). JAMA. 1964;189(10):763–764. doi:10.1001/jama.1964.03070100057011
Customize your JAMA Network experience by selecting one or more topics from the list below.